Biblio
Export 380 results:
Author Title Type [ Year
Filters: First Letter Of Last Name is E [Clear All Filters]
“Validation by Magnetic Resonance Imaging of the Diagnostic Potential of a Heptapeptide-Functionalized Imaging Probe Targeted to Amyloid-β and Able to Cross the Blood-Brain Barrier.”, J Alzheimers Dis, vol. 60, no. 4, pp. 1547-1565, 2017.
, “Visual Selective Attention Toward Novel Stimuli Predicts Cognitive Decline in Alzheimer's Disease Patients.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1339-1349, 2017.
, “Young to Middle-Aged Dogs with High Amyloid-β Levels in Cerebrospinal Fluid are Impaired on Learning in Standard Cognition tests.”, J Alzheimers Dis, vol. 56, no. 2, pp. 763-774, 2017.
, “Abnormalities of Resting State Cortical EEG Rhythms in Subjects with Mild Cognitive Impairment Due to Alzheimer's and Lewy Body Diseases.”, J Alzheimers Dis, vol. 62, no. 1, pp. 247-268, 2018.
, “Acute Stroke Care in Dementia: A Cohort Study from the Swedish Dementia and Stroke Registries.”, J Alzheimers Dis, vol. 66, no. 1, pp. 185-194, 2018.
, “Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort.”, J Alzheimers Dis, vol. 63, no. 1, pp. 373-381, 2018.
, “Age-Dependent Decrease of Mitochondrial Complex II Activity in a Familial Mouse Model for Alzheimer's Disease.”, J Alzheimers Dis, vol. 66, no. 1, pp. 75-82, 2018.
, “Albuminuria and Microalbuminuria as Predictors of Cognitive Performance in a General Population: An 11-Year Follow-Up Study.”, J Alzheimers Dis, vol. 62, no. 2, pp. 635-648, 2018.
, “Alzheimer's Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies.”, J Alzheimers Dis, vol. 62, no. 3, pp. 965-992, 2018.
, “Anticholinergic Burden and Risk of Stroke and Death in People with Different Types of Dementia.”, J Alzheimers Dis, vol. 65, no. 2, pp. 589-596, 2018.
, “Assessing Working Memory in Mild Cognitive Impairment with Serial Order Recall.”, J Alzheimers Dis, vol. 61, no. 3, pp. 917-928, 2018.
, “Association between Peripheral Leptin and Adiponectin Levels and Cognitive Decline in Patients with Neurocognitive Disorders ≥65 Years.”, J Alzheimers Dis, vol. 66, no. 3, pp. 1255-1264, 2018.
, “Atherosclerosis, Hypertension, and Diabetes in Alzheimer's Disease, Vascular Dementia, and Mixed Dementia: Prevalence and Presentation.”, J Alzheimers Dis, vol. 65, no. 4, pp. 1247-1258, 2018.
, “The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome.”, J Alzheimers Dis, vol. 63, no. 2, pp. 797-819, 2018.
, “The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome.”, J Alzheimers Dis, vol. 63, no. 2, pp. 797-819, 2018.
, “Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis.”, J Alzheimers Dis, vol. 62, no. 3, pp. 1199-1209, 2018.
, “Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: An Invaluable Tool for Clinical Diagnosis and Trial Enrichment.”, J Alzheimers Dis, vol. 64, no. s1, pp. S281-S287, 2018.
, “Changes in Expression Profiles Revealed by Transcriptomic Analysis in Peripheral Blood Mononuclear Cells of Alzheimer's Disease Patients.”, J Alzheimers Dis, vol. 66, no. 4, pp. 1483-1495, 2018.
, “Characteristics of Cognitively Normal Mexican-Americans with Cognitive Complaints.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1485-1492, 2018.
, “Class-Specific Incidence of All-Cause Dementia and Alzheimer's Disease: A Latent Class Approach.”, J Alzheimers Dis, vol. 66, no. 1, pp. 347-357, 2018.
, “Clinical-Neuropathological Correlations of Alzheimer's Disease and Related Dementias in Latino Volunteers.”, J Alzheimers Dis, vol. 66, no. 4, pp. 1539-1548, 2018.
, “Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.”, J Alzheimers Dis, vol. 61, no. 1, pp. 169-183, 2018.
, “Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.”, J Alzheimers Dis, vol. 61, no. 1, pp. 169-183, 2018.
, “Differential Effect of APOE ɛ4 Status and Elevated Pulse Pressure on Functional Decline in Cognitively Normal Older Adults.”, J Alzheimers Dis, vol. 62, no. 4, pp. 1567-1578, 2018.
, “Do Cardiometabolic Risk Factors Influence Amyloid, Tau, and Neuronal Function in APOE4 Carriers and Non-Carriers in Alzheimer's Disease Trajectory?”, J Alzheimers Dis, vol. 64, no. 3, pp. 981-993, 2018.
,